# US 2022/0024984 A1 · Maleate of scy-635 and uses thereof in medicine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0024984 A1
- Document ID: US20220024984A1
- Status: Published application
- Kind: A1
- Application number: 17/413,054
- Filed: 2018-12-14
- Published: 2022-01-27
- Earliest claimed: 2018-12-14
- Assignees: Waterstone Pharmaceuticals(Wuhan) Co., Ltd.
- Applicants: Waterstone Pharmaceuticals(Wuhan) Co., Ltd.
- Inventors: Jian CUI; Yao YU; Minglong HU
- Web page: https://patentgrep.com/patent/US20220024984A1

## CPC

- C07K 7/645: {Cyclosporins; Related peptides}
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a salt of a compound of formula (I) and uses thereof in medicine. Specifically, it relates to maleate of compound of formula (I) and pharmaceutically compositions thereof. Furthermore, the invention relates to the uses of maleate herein and pharmaceutically compositions thereof disclosed herein in the manufacture of a medicament, especially in the manufacture of a medicament for preventing, managing, treating or lessening hepatitis C virus (HCV) infection.

## Claims

### Claim 1

A salt of a compound of formula (I):
wherein the salt is maleate.

### Claim 2 (depends on 1)

The salt of claim 1, wherein a mole ratio of the compound of formula (I) to maleic acid in the maleate of the compound of formula (I) is from 1:0.9 to 1.1.2.

### Claim 3 (depends on 1)

The salt of claim 1, wherein a mole ratio of the compound of formula (I) to maleic acid in the maleate of the compound of formula (I) is 1:1.

### Claim 4 (depends on 1)

A pharmaceutical composition comprising the salt of claim 1, and a pharmaceutically acceptable excipient.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

A method of preventing, managing, treating or lessening chronic hepatitis C and hepatitis C infection, comprising administering to a patent in need of such treatment a therapeutically effective amount of the salt of claim 1.

### Claim 7

(canceled)
